Actuate Therapeutics (ACTU) Competitors $6.77 -0.28 (-3.97%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends ACTU vs. IGMS, GLUE, VERV, PROK, MREO, SANA, CRMD, ATXS, TERN, and HUMAShould you be buying Actuate Therapeutics stock or one of its competitors? The main competitors of Actuate Therapeutics include IGM Biosciences (IGMS), Monte Rosa Therapeutics (GLUE), Verve Therapeutics (VERV), ProKidney (PROK), Mereo BioPharma Group (MREO), Sana Biotechnology (SANA), CorMedix (CRMD), Astria Therapeutics (ATXS), Terns Pharmaceuticals (TERN), and Humacyte (HUMA). These companies are all part of the "pharmaceutical products" industry. Actuate Therapeutics vs. IGM Biosciences Monte Rosa Therapeutics Verve Therapeutics ProKidney Mereo BioPharma Group Sana Biotechnology CorMedix Astria Therapeutics Terns Pharmaceuticals Humacyte Actuate Therapeutics (NASDAQ:ACTU) and IGM Biosciences (NASDAQ:IGMS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, community ranking, media sentiment, institutional ownership, profitability and dividends. Does the MarketBeat Community believe in ACTU or IGMS? IGM Biosciences received 72 more outperform votes than Actuate Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformActuate TherapeuticsN/AN/AIGM BiosciencesOutperform Votes7250.70% Underperform Votes7049.30% Does the media refer more to ACTU or IGMS? In the previous week, IGM Biosciences had 1 more articles in the media than Actuate Therapeutics. MarketBeat recorded 6 mentions for IGM Biosciences and 5 mentions for Actuate Therapeutics. Actuate Therapeutics' average media sentiment score of 0.42 beat IGM Biosciences' score of 0.39 indicating that Actuate Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Actuate Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral IGM Biosciences 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders have more ownership in ACTU or IGMS? 42.8% of IGM Biosciences shares are owned by institutional investors. 57.0% of IGM Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Do analysts recommend ACTU or IGMS? IGM Biosciences has a consensus target price of $17.75, indicating a potential upside of 157.25%. Given IGM Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe IGM Biosciences is more favorable than Actuate Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Actuate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00IGM Biosciences 1 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has better earnings and valuation, ACTU or IGMS? Actuate Therapeutics has higher earnings, but lower revenue than IGM Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioActuate TherapeuticsN/AN/A-$24.75MN/AN/AIGM Biosciences$2.92M140.61-$246.42M-$3.64-1.90 Is ACTU or IGMS more profitable? Actuate Therapeutics has a net margin of 0.00% compared to IGM Biosciences' net margin of -7,534.03%. Actuate Therapeutics' return on equity of 0.00% beat IGM Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Actuate TherapeuticsN/A N/A N/A IGM Biosciences -7,534.03%-155.42%-61.04% SummaryIGM Biosciences beats Actuate Therapeutics on 8 of the 13 factors compared between the two stocks. Ad DTIWhy I'm telling friends to avoid gold stocksBack in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."And if you’d like to get your hands on this, here you go, the complete breakdown. Get Actuate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACTU and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACTU vs. The Competition Export to ExcelMetricActuate TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$132.23M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E RatioN/A10.5990.0517.18Price / SalesN/A195.801,117.14116.99Price / CashN/A57.1643.0437.86Price / BookN/A5.094.784.78Net Income-$24.75M$151.83M$120.31M$225.60M7 Day Performance-21.46%-2.13%-1.92%-1.23%1 Month Performance-24.78%-3.10%11.51%3.36%1 Year PerformanceN/A11.54%30.61%16.60% Actuate Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACTUActuate TherapeuticsN/A$6.77-4.0%N/AN/A$132.23MN/A0.0010Gap UpIGMSIGM Biosciences4.554 of 5 stars$10.57+2.5%$16.67+57.7%-12.2%$628.49M$2.13M0.00190News CoverageGLUEMonte Rosa Therapeutics1.9132 of 5 stars$10.00+6.3%$16.00+60.0%+28.3%$614.40MN/A0.0090Analyst DowngradeNews CoverageVERVVerve Therapeutics1.9654 of 5 stars$7.21+11.4%$25.75+257.1%-57.7%$610.40M$11.76M-2.93110PROKProKidney2.0368 of 5 stars$2.06-0.7%$4.50+119.0%-15.6%$599.36MN/A0.003Gap DownMREOMereo BioPharma Group2.0953 of 5 stars$3.76-0.3%$7.40+96.8%+68.3%$583.35M$1M0.0040SANASana Biotechnology2.0866 of 5 stars$2.58+12.2%$13.50+423.3%-59.8%$576.04MN/A-1.84328CRMDCorMedix1.8419 of 5 stars$9.34-1.7%$15.20+62.7%+147.0%$566.75M$60,000.000.0030Analyst ForecastNews CoveragePositive NewsATXSAstria Therapeutics2.0732 of 5 stars$10.04-3.0%$25.60+155.0%+58.0%$566.56MN/A0.0030News CoverageTERNTerns Pharmaceuticals4.2412 of 5 stars$6.56+0.2%$18.30+179.0%-6.8%$557.21M$1M-5.4940Positive NewsGap DownHUMAHumacyte3.3447 of 5 stars$4.31-10.8%$13.00+201.6%+69.3%$542.46M$1.57M-3.22150Analyst ForecastGap Up Related Companies and Tools Related Companies IGMS Competitors GLUE Competitors VERV Competitors PROK Competitors MREO Competitors SANA Competitors CRMD Competitors ATXS Competitors TERN Competitors HUMA Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ACTU) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Actuate Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Actuate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ACTU Stock Alerts